MedWatch

Novo Holdings CEO: "Novo Nordisk Foundation's strategy must evolve"

According to CEO Kasim Kutay, Novo Holdings is a somewhat atypical asset manager, which on a mandate from its ownership foundation creates a two-digit return on its investments. It is both an interesting and scary model, which in future will force the Novo Noridsk Foundation to branch out to other geographical areas, he predicts.

Photo: Novo A/S PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Her er de vigtigste nyheder fra MedWatch i uge 38

En "digital transformation" i Novo Nordisks F&U-afdeling, som koster 400 medarbejdere jobbet, stjal fokus i uge 38, hvor Zealand Pharma ramte plet i et afgørende fase 3-studie og Coloplast holdt kapitalmarkedsdag. MedWatch giver dig her overblikket over ugens vigtigste begivenheder.

CHMP får ny, tysk formand

Ved sit septembermøde har EU's ekspertkomité på ibrugtagning af nye lægemidler, CHMP, valgt en ny formand for de næste tre år, ny næstformand skal vælges i næste måned.

Related articles